event-trade登录编辑
PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 07:52:00·⟳ 抓取 07:59:36 +7m36s·⚡ 决策 08-25 08:02:38 +3m02s·63.5 天前

Rosen律所再次提醒Capricor证券欺诈集体诉讼首席原告截止日

本条为Rosen律所对既有CAPR证券欺诈集体诉讼的重复提醒,新增信息限于首席原告截止日招募;真正影响CAPR.US的Deramiocel监管争议和诉讼公告已提前公开传播,边际预期差不足以支持新开空。

📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of s…
不做 Capricor Therapeutics, Inc.(CAPR.US)
不做:本条是既有CAPR证券诉讼的重复律师提醒,核心FDA和诉讼事实已提前公开传播;缺少新增监管、法院或经营损害事实,也没有可执行真实报价支持开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Capricor的Deramiocel BLA统计分析争议和FDA咨询委员会负面投票是公司级利空,但这些事实早已在7月底至8月初进入市场并引发同类诉讼公告。本次PRNewswire稿件没有新增FDA动作、法院裁定、赔偿金额或经营损害,只是律师事务所再次招募投资者;直接交易载体扫描未发现除CAPR.US外的可比直接产品,最终不做新交易。

🔎 新鲜度:最早出现 2026-08-05 · 扩散 high · price-in 风险 high ↗ ↗ ↗

消息传播链

  1. 2026-07-27官方确认/否认Capricor Therapeutics一手源原文 ↗
    公司回应FDA会前材料,Deramiocel统计分析计划争议在证券诉讼提醒前已公开。
  2. 2026-07-30官方确认/否认Capricor Therapeutics 8-K一手源原文 ↗
    公司披露FDA咨询委员会对Deramiocel有效性证据的投票结果为3票赞成、9票反对。
  3. 2026-08-05财经媒体扩散GlobeNewswire/Hagens Berman非一手原文 ↗
    Hagens Berman已披露CAPR证券欺诈集体诉讼、类别期间和2026年9月28日首席原告截止日。
  4. 2026-08-08财经媒体扩散PRNewswire/Rosen Law Firm非一手原文 ↗
    Rosen律所此前已发布同类CAPR诉讼招募公告,说明本次8月24日稿件不是首次披露。
  5. 2026-08-24 23:52 UTC财经媒体扩散PRNewswire/Rosen Law Firm非一手原文 ↗
    本次信号为Rosen律所再次提醒投资者加入既有诉讼和首席原告截止日。

关键理由

  • 事件本身偏负面,因为诉讼继续指向Deramiocel临床数据统计分析和BLA审批风险。
  • 但本次新增事实很弱,主要是律师招募和2026年9月28日首席原告截止日提醒。
  • 量级无法升级为交易:本条没有披露赔偿金额、禁令或审批结果,不能估算新增损失占收入、市值或现金的比例。

主要风险

  • 若后续FDA正式拒批、发出CRL或法院披露实质不利进展,CAPR.US可能出现新的强空催化。
  • 缺少实时可执行报价和正式先例测算,不能把重复律师提醒转化为可靠入场价、止盈止损和仓位。

反向证据

  • 做空前查反向 · 来源 web · 日期 2026-08-13 · 影响 weakens
    公司此前仍称Deramiocel BLA处于FDA审评中,重复诉讼提醒不足以替代新的监管否定事件。
    检索:Capricor Deramiocel BLA FDA review Q2 2026 corporate update 原文 ↗
  • 做空前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
    多家律所已在8月初公开同类诉讼和截止日,削弱8月24日提醒的新鲜度和短线做空edge。
    检索:Capricor class action September 28 2026 lead plaintiff deadline August 2026 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例不足使止盈止损和仓位无法量化;结合传播链显示无新增事实,最终维持AVOID。

方向:证券诉讼首发或监管实质进展通常偏负面,但重复律师提醒的边际方向弱,不能单独支撑强空。

涨幅量级:没有高相似、锚点干净且完成event_study的样本可用于校准CAPR.US短线跌幅。

形态:本次更接近重复扩散和律师广告,不是监管首发、公司公告首发或法院实质节点。

原文全文

展开原文 · 4,273 字
NEW YORK, Aug. 24, 2026 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, a cell therapy; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (the "BLA"); (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about Capricor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。